Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 7, 2026Indian Journal of DermatologyOpen Access

Real-World Efficacy and Safety of Ixekizumab in the Treatment of Psoriasis: A Case-Series from Indian Sub-Continent

View Full Paper
Ask AI
Bookmark
Share

Authors

ADAbhishek DeSASK Shahriar AhmedDCDipanjan Chakraborty

Discussion

Loading...

Member takes

Overview

Case-series reporting ixekizumab's effectiveness in reducing psoriasis severity, suggesting its safety in patients.

Key Points

  • The aim is to evaluate the real-world efficacy and safety of ixekizumab in treating psoriasis.
  • Case series of 22 patients with moderate to severe psoriasis treated with ixekizumab.
  • Evaluated patients over 14 weeks of treatment.
  • Assessed psoriasis severity with PASI, BSA, and sPGA scores at multiple follow-ups.
  • Mean PASI decreased from 30.82 to 2.82 after 14 weeks.
  • PASI75, PASI90, and PASI100 were achieved by 95.45%, 68.18%, and 27.27% of patients, respectively.
  • Significant reduction in PASI, BSA, and sPGA scores observed by 2 weeks and maintained through 14 weeks.
  • No significant side effects were reported during the treatment period.

Cite This Study

De et al. (2026) studied this question.

synapsesocial.com/papers/69abc2075af8044f7a4eb436https://doi.org/10.4103/ijd.ijd_133_24
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ixekizumab in nail psoriasis2020 · 3 citations
  2. 2Biologics use in Indian psoriasis patients2016 · 13 citations
  3. 3Characteristics and sources of tissue-resident memory T cells in psoriasis relapse2023 · 44 citations
  4. 4Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis2016 · 849 citations
  5. 5Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis2012 · 944 citations